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Abstract
Purpose Helper CD4+ T cells presumably play a major role in
controlling cytomegalovirus (CMV) by providing help to spe-
cific B and CD8+ cytotoxic T cells, as well as through
cytotoxicity-mediated mechanisms. Since CMV glycoprotein
B (gB) is a major candidate for a subunit vaccine against CMV,
we searched for gB-epitopes presented by human leukocyte
antigen (HLA)-class II molecules.
Methods Dendritic cells obtained from CMV-seropositive
donors were loaded with a recombinant gB and co-cultured
with autologous CD4+ T cells. Microcultures that specifically
recognized gB were cloned by limiting dilution using autolo-
gous Epstein-Barr virus (EBV)-immortalized B cells pulsed
with gB as antigen-presenting cells. To pinpoint precisely the
region encoding the natural epitope recognized by a given
CD4+ clone, we assessed the recognition of recombinant
Escherichia coli expressing gB-overlapping polypeptides af-
ter their processing by autologous EBV-B cells.
Results We isolated several gB-specific CD4+ T-cell clones
directed against peptides gB190-204, gB396-410, gB22-36 and
gB598-617 presented by HLA-DR7, HLA-DP10 and HLA-
DP2. While their precise role in controlling CMV infection
remains to be established, gB-specific CD4+ T cells are likely
to act by directly targeting infected HLA-class II cells in vivo,
as suggested by their recognition of EBV-B cells infected by
the Towne CMV strain.
Conclusions The characterization of such gB-epitopes pre-
sented by HLA-class II should help to understand the contri-
bution of CD4+ T-cell responses to CMV and may be of
importance both in designing a vaccine against CMVinfection
and in immunomonitoring of subjects immunized with recom-
binant gB or with vectors encoding gB.
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Introduction
Human cytomegalovirus (CMV) is a ß-herpesvirus that shares
common biological properties with other herpesviruses, such
as persistence and latency in the host. Several lines of evi-
dence indicate that both humoral and cellular immunity to
CMV can reduce the frequency and severity of the disease
[1–6]. So far, much importance has been placed on the role of
cytotoxic T cells (CTL) in the recognition of CMV-infected
cells, and the CD8+ CTL response to CMVantigens has been
widely investigated using various reliable tools and methods
[7–10]. There is however increasing evidence that CD4+ T
cells also play a critical role in the control of CMV infection,
reactivation and vertical transmission [3, 11]. However, the
fine specificity pattern and nature of the CD4 response remain
largely unsolved.
Due to its ability to elicit neutralizing antibodies (Abs)
during infection, human CMV envelope gB is the leading
subunit vaccine candidate [12–14]. A recent clinical report
shows that the administration of a recombinant human CMV
P. Chaux (*)
Discovery Department, Sanofi Pasteur,
1541 Avenue Marcel Mérieux,




Sanofi Pasteur Biologics Co,
38 Sidney St,
Cambridge, MA 02139, USA
Present Address:
H. Bisceglia :Y. Girerd-Chambaz :N. Burdin : P. Chaux
Sanofi Pasteur,
1541 Avenue Marcel Mérieux,
69280 Marcy l’Etoile, France
J Clin Immunol (2012) 32:1305–1316
DOI 10.1007/s10875-012-9732-x
gB prevents maternal infection and tended to decrease congen-
ital CMV infection [15]. Interestingly, a recent sub-study
showed that both CMV-specific Abs and CD4+ T-cell
responses can be boosted after vaccination with gB formulated
in MF59, an oil-in-water emulsion, in women with chronic
CMV infection [16]. Another study, attempting to understand
the correlates of immune protection during the primary im-
mune response to CMV, determined that the formation of
effector memory CD4+ T cells was necessary for recovery
from infection [17]. Thus, a deeper knowledge of the contri-
bution of the CD4+ T-cell mediated immune response is essen-
tial to study the protective activity of the gB vaccine candidate.
In the past few years, much research has focused on the use of
tetramers, or on functional assays such as ELISPOT and intra-
cellular cytokine staining (ICS) to explore CD4+ T cells
responses in various disease settings or after vaccination in
humans [18–21]. ELIPSOT and ICS assays commonly use
overlapping pools of peptides to induce T cells to produce
cytokines as an indication of their function. Although success-
ful, these assays usually require several rounds of screening and
so, depending on the size of the peptide library, might be costly,
time-consuming and require large quantities of sample which
may be unavailable.
By stimulating CD4+ T cells from CMV-seropositive
donors with gB-primed autologous DCs and by using a simple
and cost-efficient procedure based on the exogenous pathway
to take up and process gB polypeptides expressed in recom-
binant bacteria, we derived several CD4+ T-cell clones and
identified four gB epitopes presented by HLA-DR7, DP10
and DP2 molecules. The identification of gB-derived peptides
such as those reported here may be of use in tracking clonal
expansion of gB-specific CD4+ T cells during CMV infection
and inmonitoring the immune response of subjects vaccinated
with recombinant gB or with recombinant vectors coding for
gB, provided they allow for a significant coverage of the
population on the basis of the frequency of the relevant
HLA-class II alleles.
Methods
Media, Reagents and Cells
Culture media were RPMI (for EBV-B cells or dendritic cells
(DCs)) and IMDM (for CD4+ T cells) supplemented with
penicillin (100 U/ml), streptomycin (100 mg/ml), glutamine
(2 mM) (Life Technologies, Gibco-BRL) and 10 % Fetal
Bovine Serum (FBS) or 10 % human serum, respectively.
The recombinant CMV gB used in the present work was
obtained after mutagenesis to eliminate a cleavage site, and
the transmembrane region was deleted to facilitate secretion of
the glycosylated protein in Chinese hamster ovary cell culture
[13]. Blood cells were collected at the Etablissement Français
du Sang (EFS, Lyon, France) as buffy coat preparations from
anonymous healthy, CMV-positive blood donors after in-
formed consent and following EFS guidelines. Peripheral blood
mononuclear cells (PBMCs) were isolated by density gradient
centrifugation on Lymphoprep (Axix Shield PocAS, Oslo,
Norway). Immature DCs were generated from CD14+ PBMCs
isolated by positive selection using an anti-CD14 monoclonal
antibody (mAb) coupled to magnetic microbeads (Miltenyi
Biotech, Paris, France) and by sorting through a MACS®
followed by 5 days of culture in complete RPMI medium
supplemented with 10 U/ml IL-4 (Brucells, Brusssel, Belgium)
and 50 ng/mlGM-CSF (PeproTech, Neuilly Sur Seine, France).
Cultures were fed on days 2 and 4 by adding IL-4 and GM-
CSF. CD4+ T lymphocytes were isolated from CD14- PBMCs
by positive selection using an anti-CD4 mAb coupled to mag-
netic microbeads (Miltenyi Biotech, Paris, France) and by
sorting through a MACS®, as recommended by the manufac-
turer. The CD4+ T lymphocytes were kept frozen and were
thawed the day before co-culture with DCs. Recombinant IL-2,
IL-4, IL-6, IL-7 and IL-12 cytokines were purchased from
AbCys S.A. (Paris, France). Anti-HLA DP, anti-HLA
DR, anti-HLA DQ or anti-HLA (DP, DQ, DR) Abs and
conjugated Abs anti-CD3-PE, antiCD4-PerCP-Cy5-5, anti-
Granzyme B (GrB)-FITC were purchased from Becton
Dickinson Biosciences (San Jose, California) and Antibodies-
online GmbH (Aachen, Germany).
Mixed Lymphocyte/Dendritic Cell Culture
Immature DCs (5×105/ml) were incubated at 37 °C, 5 % CO2
for 18–20 h in complete medium supplemented with IL-4
(10 U/ml), GM-CSF (50 ng/ml) and a synthetic TLR4 agonist
(1 ng/ml; EISAI, Japan) in the presence of recombinant gB
(10 μg/ml). Cells were washed and added at 104 per round-
bottom microwell to 105 autologous CD4+ T lymphocytes in
200 μl IMDM supplemented with 10 % human serum (here-
after referred to as complete IMDM) in the presence of IL-6
(1,000 U/ml) and IL-12 (10 ng/ml). The CD4+ T lymphocytes
were stimulated on days 7, 14 and 21 with autologous DCs
freshly loaded with gB and were grown in complete IMDM
supplemented with IL-2 (10 U/ml) and IL-7 (5 ng/ml). The
microcultures containing proliferating CD4+ T cells were then
analyzed for their specificity at least 1 week after the last
stimulation. Autologous EBV-B cells were incubated or not
for 18–20 h in the presence of 10 μg/ml of recombinant gB,
then washed and plated at 104 cells per round-bottom micro-
well together with 3×103 autologous CD4+ T lymphocytes in
200μl of complete IMDM supplementedwith IL-2 (25 U/ml).
After 20 h, the supernatant was collected and the IFN-γ
content was measured by ELISA (Becton Dickinson, San
Jose, California). Inhibition with anti-DP, anti-DR, anti-DQ
or anti-(DP, DQ, DR) Abs was performed by adding them at a
concentration of 10 to 25 μg/ml during the experiment.
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CD4+ T-cell Clones
Cells from positive microcultures were cloned by limiting
dilution, using as stimulator cells either mytomicin C -treated
(Roche; 0.1 mg/ml PBS) or X-irradiated autologous EBV-B
cells previously loaded with gB (5×103 to 2×104 cells). CD4+
T-cell clones were grown in complete IMDM supplemented
with IL-2 (50–150 U/ml) and occasionally IL-7 (5 ng/ml). The
clones were divided and supplemented with fresh culture me-
dium and stimulator cells (2×105 per well in a 48-well plate) at
1- to 2-week intervals. Established CD4+ T-cell clones were
tested for IFN-γ production after stimulation with autologous
EBV-B cells pulsed with either gB, recombinant bacteria
expressing the full gB or its sub-fragments, or gB-derived
synthetic peptides.
Construction of pGEX and pET28c Containing gB-cDNA
The full sequence encoding recombinant human CMV gB [13]
was cloned into the pET28c expression vector (Novagen,
EMDChemicals, Inc. Gibbstown, US). Then, four overlapping
fragments of the gB coding sequence (gB1-218, gB199-417,
gB398-617 and gB598-806 hereafter referred as to A, B, C and
D, respectively) were subcloned into the pGEX-4T-1 plasmid
using gB-specific primers containing the NotI and BamHI
restriction sites in fusion with the glutathione serine transferase
(GST) [22]. Each of the four sequences, A, B, C and D, was
then subcloned by PCR into pGEX-4T-1 in five overlapping
sequences coding for peptides of ~60 amino acids (aa) that
overlap by ~20 aa (hereafter referred as to A1 to A5, B1 to B5,
C1 to C5 and D1 to D5, respectively). The PCR products were
purified using a QIAquick PCR purification kit (Qiagen, Cour-
taboeuf, France), digested using the BamHI and NotI restric-
tion enzymes and the inserts were cloned into the pET28c
plasmid using the Rapid DNA ligation kit (Roche). Plasmids
were purified with the Biorobot 9600 using the NucleoSpin®
Plasmid extraction kit (Qiagen), and the sequence of the inserts
was systematically checked. E. coli BL21 bacteria were trans-
formed by electroporation with the various recombinant plas-
mids and selected with ampicillin (50 μg/ml).
Recombinant Bacteria Recognition Assay
The procedure used to identify the natural peptide recognized
by each of the CD4+ clones was based on the exogenous
pathway to take up and process polypeptides encoded by
overlapping gB cDNA fragments expressed in recombinant
BL21 bacteria. To obtain a standard amount of bacteria con-
taining the various fragments of gB cDNA, the recombinant
bacteria representing each gB polypeptide were amplified in
LB medium containing ampicillin (50 μg/ml) and kanamycin
(7.5μg/ml), at 37 °C under agitation until an OD600 of 0.5 was
reached. Isopropyl β-D-thiogalactoside (IPTG; 1 mM)
was added to induce protein expression. Incubation was con-
tinued under agitation for 4 h at 37 °C, and the recombinant
bacteria were then centrifuged at 2500 rpm for 15 min. The
supernatant was discarded and the bacteria were suspended in
PBS and kept frozen at −80 °C until use. The recombinant
bacteria (5 μl) expressing each gB sub-fragment were added
to EBV-B cells and plated out in 96-well U-bottom plates
(2×104 cells/well) in 50 μl IMDM/10 % FBS supplemented
with 20 μg/ml gentamycin. The CD4+ T-cell clones (3 to 5×
103 cells/well) were added extemporaneously in 100 μl
IMDM/10% human serum supplemented with IL-2 (25 U/ml)
and gentamycin (20 μg/ml). After 18 h of co-culture, the
supernatants were harvested and the amount of IFN-γ released
by the specific CD4+ T-cell clones was measured using a
standard ELISA.
Recognition Assays with Peptides or with Towne Virus
Infected Cells
Peptides were synthesized on solid phase using F-moc for
transient NH2-terminal protection andwere characterized using
mass spectrometry (Neosystem, Strasbourg, France). All pep-
tides were controlled by mass spectrometry and were ≥80 %
pure, as indicated by analytical HPLC. Lyophilized peptides
were kept frozen after dissolution in DMSO. CD4+ T-cell
clones were incubated with either autologous HLA-matched
or HLA-mismatched EBV-B cells that had been pre-incubated
for 2 h with each individual peptide, the indicated concentra-
tions representing their concentrations during the incubation
step. They were distributed at 20 000 cells per round-bottom
microwell together with 3 to 5×103 CD4+ T lymphocytes in
150 μl of complete IMDM supplemented with IL-2 (20 U/ml).
Occasionally, CD4+ T-cell clones were incubated with autolo-
gous EBV-B cells infected with the Towne CMV laboratory
strain at a multiplicity of infection of 10:1 for 1 h, 24 h prior to
use. The supernatants were harvested after 18 to 36 h and
assayed for IFN-γ by ELISA.
Flow Cytometry
For analysis of expression of surface markers, a total of
2×105 cells were incubated with fluorescent labeled conju-
gated mAbs according to manufacturer’s instructions for
30 min at 4 °C. Samples were fixed and permeabilized
(BD Biosciences) and then stained for GrB expression accord-
ing to the recommended procedure. Flow cytometry analysis
was performed by FACSCalibur flow cytometer and Cell-
Quest software (BD Biosciences).
HLA-class II Genotyping
HLA-class II genotyping was performed by PCR from ge-
nomic DNA according to Dynal Biotech procedures (Dynal
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AllSet+™ SSP DR “low resolution”) by C.Ris Pharma (Saint
Malo, France) [23].
Results
The experiments were performed with blood cells from two
CMV-seropositive donors, using CD4+ T lymphocytes as re-
sponder cells and autologous DCs loaded with recombinant gB
as stimulator cells. Responder CD4+ T cells were stimulated at
weekly intervals. After a resting period of 2 weeks, the micro-
cultures that specifically produced high levels of IFN-γ after
stimulation with autologous EBV-B cells loaded with gB were
cloned by limiting dilution in the presence of IL-2. EBV-B cells
loaded with gB were either irradiated or mitomycin-C treated
and used as stimulating cells for the cloning step because of the
limited supply of autologous DCs. After a few weekly re-
stimulations, growing CD4+ clones were tested for their ability
to recognize autologous EBV-B cells loaded with gB and were
further characterized (Fig. 1a). In order to identify the natural
gB-peptide recognized by CD4+ T cell clones, recombinant E.
coli expressing full gB or overlapping gB-polypeptides were
produced. As a first step, human CMV-gB cDNA fragments
was cloned into the pGEX expression vector and used to
transform E. coli. After induction of protein synthesis, recom-
binant bacteria were incubated directly with autologous EBV-
transformed B cells that were subsequently used to stimulate
autologous CD4+ clones. The use of minigenes coding for gB
fragments expressed in recombinant bacteria precisely pin-
pointed the region encoding the antigenic peptide recognized
by a given CD4+ clone, and avoided the synthesis and the
screening of a large library of overlapping peptides (Fig. 1b).
Clone 1A10 Recognizes Peptide PDDYSNTHSTRYVTV
on HLA-DR7
Clone 1A10 was obtained by limiting dilution from a micro-
culture of CD4+ T lymphocytes from donor CMV001, using
autologous EBV-B cells loaded with gB as stimulator cells.
Clone 1A10 recognized autologous EBV-B cells loaded either
with gB or with recombinant E. coli bacteria expressing either
fragment A (gB1-218) or sub-fragment A5 (gB158-218) (Fig. 2a).
To precisely identify the gB peptide recognized by the clone,
we screened a set of 12 synthetic peptides of 16 aa, overlapping
by 12 aa and covering the gB158-218 sequence. Autologous
EBV-B cells were incubated with each individual peptide
at a concentration of ~1 μM and were tested for their
recognition by CD4+ T-cell clone 1A10 in an IFN-γ ELISA.
Clone 1A10 recognized two overlapping peptides, namely
MQLMPDDYSNTHSTRY (gB186-201) and PDDYSNTH-
STRYVTVK (gB190-205) (Fig. 2b). Unlike peptides presented
by HLA-class I molecules, those presented by HLA-class II
usually vary in length and tolerate extensions at both the NH2
and COOH termini because they are not attached by their ends
in the HLA groove. It is therefore difficult to define the length
of the peptides precisely. We tested a large number of gB
peptides of different lengths and concluded that the optimal
sequence of the peptide recognized by clone 1A10 is
PDDYSNTHSTRYVTV (gB190-204). Half-maximum value of
IFN-γ production was obtained by incubating stimulator cells
with ~30 ng/ml of this peptide (~17 nM) (Fig. 2c). This com-
pares favorably with the results obtained with other epitopes
recognized on HLA-class II molecules by CD4+ T cells, and
this is in accordance with the IC50 prediction value of 33 nM
determined using SMM-align, a stabilization matrix alignment
method available online (http://tool.immuneepitope.org). Rec-
ognition by clone 1A10 of cells loaded with gB was abolished
by an anti-DR Ab (Fig. 2d). The serological equivalent for
HLA genotyping of donor CMV001 was DR1 DR7 DR53.
To identify the HLA-DRmolecule that presents the gB-derived
peptide to clone 1A10, the gB190-204 peptide was loaded on a
panel of partially HLA-matched or mismatched EBV-B cell
lines. All and only peptide-sensitized cell lines expressing
HLA-DR7 were recognized by clone 1A10 (Fig. 2e). Of note,
this immunogenic peptide was confirmed as being naturally
processed and presented by HLA-DR7 utilizing the ProPre-
sent™ technology, a mass spectrometry-based analysis (data
not shown) (ProImmune, Oxford, UK). The PDDYSNTH-
STRYVTV sequence contains a gB epitope that has in fact
been previously identified by other investigators. Elkington
et al. isolated a human cytotoxic CD4+ T-cell clone that
recognized the DYSNTHSTRYV peptide (gB192-202) in as-
sociation with HLA-DR7 [24]. This 11-aa sequence, named
DYS, was the most active in a CTL assay under limiting
dilution, and DYS-specific CD4+ T cells showed extreme
conservation of T-cell receptor usage, which suggests a
strong clonal selection for its recognition [25]. HLA-DR7
is expressed in ~23 % of Caucasians, ~25 % of Africans
and ~6 % of Asians.
Clone 2G12 Recognizes Peptide HSRSGSVSQRVTSSQ
on HLA-DP10
A second CD4+ T-cell clone with a different specificity
was obtained from the microcultures of CD4+ T lym-
phocytes from donor CMV001. Clone 2G12 recognized
autologous EBV-B cells loaded with gB, or with re-
combinant bacteria expressing either gB fragment A
(gB1-218) or sub-fragment A1 (gB1-57) (Fig. 3a). To
identify the gB peptide recognized by clone 2G12, a
set of 12 peptides of 16 aa was screened. The peptides
overlapped by 12 aa and covered the gB1-57 sequence.
CD4+ T-cell clone 2G12 recognized two overlapping
peptides, namely TSAAHSRSGSVSQRVT (gB18-33) and
HSRSGSVSQRVTSSQT (gB22-37) (Fig. 3b). In order to
define the minimal peptide recognized by clone 2G12, a set
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of 9 overlapping peptides from 12 to 15 aa was screened. The
nine overlapping peptides were all recognized by clone 2G12
and stimulated strong production of IFN-γ, although peptide
HSRSGSVSQRVTSSQ (gB22-36) showed the strongest activ-
ity and was the most active in limiting dilution (Fig. 3c). We
concluded that the shortest peptide well recognized by clone
2G12 is gB22-36. Half-maximum value of IFN-γ production
was obtained by incubating stimulator cells with ~50 ng/ml of
this peptide (~30 nM). Recognition by clone 2G12 of cells
loaded with gB was abolished by an anti-HLA-(DP, DQ, DR)
and also by an anti-DPAb, but not by anti-DR or DQ specific
Abs (Fig. 3d). CMV001 donor was typed DP1 DP10. To
identify the HLA-DP molecule that presents the gB peptide
recognized by clone 2G12, gB was loaded on a panel of
allogeneic EBV-B cell lines. All and only the peptide-
sensitized HLA-DP10 cell lines tested were recognized by
clone 2G12 (Fig. 3e). HLA-DP10 is expressed in ~3 % of
Caucasians and ~1 % of Asians.
Clone 2C4 Recognizes FETTGGLVVFWQGIK, a Peptide
with a Strong Affinity for HLA-DR7
A third CD4+ T-cell clone, called 2C4, was obtained from
CMV001 donor, and was also very well stimulated by cells
loaded with gB or with recombinant bacteria expressing either
B (gB199-417) or B5 polypeptides (gB359-417) (Fig. 4a).
We screened a set of 7 synthetic overlapping peptides and
showed that clone 2C4 recognized GNVSVFETTGGLVVFW
(gB391-406) and VFETTGGLVVFWQGIK (gB395-410) (Fig. 4b).
The binding prediction (http://tool.immuneepitope.org) analysis
indicated that the gB396-410 peptide (FETTGGLVVFWQGIK)
was a very good binder for HLA-DRB1*0701 (score 231659.5
versus 307.2 for HLA-DRB1*0101). Half-maximum value of
IFN-γ production was obtained by incubating the stimulator
cells with 10 ng/ml of this peptide (~6 nM) (Fig. 4c). In
accordance with these data, recognition by clone 2G12 of cells
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Fig. 1 Overview of the
procedure used to obtain
and characterize anti-gB
CD4+ T-cell clones
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HLA-(DP, DQ, DR) and also by an anti-DR Ab, but not by an
anti-DP Ab (Fig. 4d), suggesting that gB396-410 is presented to
clone 2C4 in association with HLA-DR7. Unfortunately, we
were unable to expand this clone in vitro to further confirm the
HLA-class II presenting molecule.
Clone B3A5 Recognizes Peptide YEYVDYLFKRMID
on HLA-DP2
Clone B3A5 was obtained from CMV016, a second CMV-


























































































































































































Fig. 2 Characteristics of clone 1A10. a Recognition of EBV-B cells
loaded with recombinant gB-expressing bacteria by CD4+ T-cell clone
1A10. CD4+ T-cell clone 1A10 (3000 cells) were co-cultured for 20 h with
autologous CMV001 EBV-B cells (20 000 cells/well) loaded or not with
gB (10 μg/ml) or with recombinant bacteria that expressed each of the 4
overlapping gB constructs (A, B, C, D) or each of five overlapping
constructs spanning the A (A1 to A5), B (B1 to B5), C (C1 to C5) or D
(D1 to D5) fragments. The amount of IFN-γ secreted in the supernatant of
the co-cultures was measured using standard ELISA. The results shown
represent an average of duplicate co-cultures. b Recognition of gB over-
lapping peptides by CD4+ T-cell clone 1A10. EBV-B cells were incubated
for 2 h with each of the gB overlapping peptides (1 μg/ml). CD4+ T-cell
clone 1A10 (3000 cells) were then co-cultured with autologous peptide-
pulsed EBV-B cells (20 000 cells) for 18 h. IFN-γ production in the
supernatant was measured by ELISA. The results shown represent the
average of triplicate cultures. c Identification of the minimal gB epitope
recognized by CD4+ T-cell clone 1A10. EBV-B cells were distributed in
microwells (2×104 cells) and incubated for 2 h with various concentrations
of each individual peptide. A total of 3 to 5×103 cells from autologous
CD4+ T-cell clone 1A10 was added and the presence of IFN-γ production
in the supernatant was measured by ELISA after overnight culture. The
results shown represent an average of duplicate cocultures. d Inhibition of
the gB peptide recognition by anti-HLA-DP, -DQ or -DR Abs. Autologous
EBV-B cells were incubated with 10 μg/ml of recombinant gB for 20 h.
CD4 T-cell clones (3 000 cells) were then co-cultured with 20 000 protein-
loaded EBV-B cells for 20 h. Inhibition with anti-HLA class II mAbs was
performed by addition of 10 μg/ml of mAb during the co-culture. IFN-γ
production was measured by ELISA after 18 h. e HLA-class II restriction
analysis of the gB epitope. The gB-specific CD4+ T-cell clone 1A10 was
exposed to gB-loaded autologous or allogeneic EBV-B cells. IFN-γ pro-
duction was measured by ELISA after overnight co-culture. The results
shown represent the average of triplicate co-cultures
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loaded with gB or with recombinant bacteria expressing C
(gB398-617) and D (gB598-806) gB-overlapping fragments. Ac-
cordingly, the 2 overlapping sub-fragments C5 (gB558-617) and
D1 (gB598-657) also induced high levels of IFN-γ secretion
(Fig. 5a). The C5 and D1 polypeptides shared the 21-aa
peptide sequence NSAYEYVDYLFKRMIDLSSI (gB598-617)
that therefore contained the optimal sequence of the natural
peptide recognized by clone B3A5. The recognition of gB-
loaded cells by CD4+ clone B3A5 was inhibited by an anti-
HLA-(DP, DQ, DR) and by anti-HLA-DP Abs, but not by
anti-DR or anti-DQ specific Abs (Fig. 5b). CMV016 donor
was typed HLA-DP2 DP4. Interestingly, HLA-DP4 and
HLA-DP2 were suggested to form a supertype of HLA-class
II molecules on the basis of homology in the peptide-binding
pockets P1 and P6 and are expected to share a common
repertoire of peptides [26]. The HLA-DP4 peptide-binding
site consists of two large aromatic pockets at positions 1
(P1) and 6 (P6) that accommodate aromatic/hydrophobic res-
idues such as Phe, Tyr, and Leu. Based on this model, the 13-
aa peptide, YEYVDYLFKRMID (gB601-613), is thought to
contain three putative HLA-DP4 binding motifs, the major
P1, P4 and P6 anchors being Tyr, Tyr and Phe, respectively
[26]. Therefore, gB601-613 appeared as the minimal gB-derived
epitope recognized by clone B3A5 in association with HLA-
DP. Peptide titration analysis revealed a high avidity with a
half-maximum value of IFN-γ production obtained by incu-
bating the stimulator cells with ~10 ng/ml of this peptide
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Fig. 3 Characteristics of clone 2G12. The procedure used for clone 2G12
was the same as the one described in Fig. 2. a Recognition of EBV-B cells
loaded with recombinant gB-expressing bacteria by CD4+ T-cell clone
2G12. b Recognition of gB overlapping peptides by CD4+ T-cell clone
2G12. c Identification of the minimal gB epitopes recognized by CD4+ T-
cell clone 2G12. d Inhibition of the gB peptide recognition by anti-HLA-
DP, -DQ or -DR Abs. e HLA-class II restriction analysis of the gB epitope
recognized by CD4+ T-cell clone 2G12
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gB601-613 peptide could be presented in association with HLA-
DP4 and/or HLA-DP2 to anti-gB CD4+ T cell clones.
Attempts to label either PBMCs isolated from donor
CMV016 as well as CD4+ T-cell clone B3A5 using a PE-
conjugated HLA-DP4 tetramer loaded with the YEYV-
DYLFKRMID peptide (kindly provided by Dr. E. James,
the Benaroya Research Institute, Seattle, [27]) failed (data
not shown). These data suggest that, for donor CMV016, the
YEYVDYLFKRMID epitope is strictly presented in associa-
tion with HLA-DP2. In line with these data, all gB-loaded
HLA-DP2 cell lines were recognized by B3A5 whereas homo-
zygous HLA-DP4 EBV-B cells pulsed with the YEYV-
DYLFKRMID peptide did not stimulate B3A5 (Fig. 5d).
HLA-DP2 is expressed in ~25 % Caucasians whereas HLA-
DP4 is expressed in ~60%.Whether this peptide is presented in
association with HLA-DP4 molecules in other CMV-
seropositive subjects deserves further investigation.
Presentation of CMV gB to CD4+ T Cells by EBV-B Cells
Infected with the Towne CMV Strain
One essential feature of functional CD4+ Tcells is their ability
to recognize naturally processed antigens. EBV-B cells,
known to express HLA-class II molecules, infected with the
Towne CMV laboratory strain stimulated the gB-specific
clones B3A5 and 1A10 to produce IFN-γ at levels similar to
that induced by autologous EBV-B cells that present either
soluble gB or the relevant gB-derived peptide (Fig. 6a and b).
Our results are in accordancewith published data showing that
gB synthesized endogenously in CMV-infected cells can
reach the HLA-class II presentation pathway [28] and suggest
that the gB-derived epitopes sorted to endosomes of HLA-
class II of CMV-infected cells are efficiently presented to anti-
gB CD4+ T-cell clones in vivo. Interestingly, we showed that
around 20 % of CD4+ T-cell clone B3A5 expressed the
cytolytic molecule GrB, suggesting that clone B3A5 is capa-
ble of performing cytolysis through this pathway (Fig. 6c).
Discussion
A comprehensive understanding of the human CD4+ T-cell
response to CMV remained hampered by limitations in the
techniques and tools used in assaying for specific CD4+ T
cells. The CMV-specific response in immunocompetent sub-
jects has been evaluated by ICS following stimulation of
CD4+ T cells with crude extracts of CMV proteins prepared
from infected cells or with peptide libraries and has revealed
broad antigen recognition [29, 30]. When overlapping 15-mer





























































































































Fig. 4 Characteristics of clone 2C4. The procedure used for clone 2C4
was the same as the one described in Figs. 2 and 3. a Recognition of
EBV-B cells loaded with recombinant gB-expressing bacteria by CD4+
T-cell clone 2C4. b Recognition of gB overlapping peptides by CD4+
T-cell clone 2C4. c Identification of the minimal gB epitope recognized
by by CD4+ T-cell clone 2C4. d Inhibition of the gB peptide recogni-
tion by anti-HLA-DP, -DQ or -DR Abs
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were used to stimulate CD4+ T cells in CMV-infected sub-
jects, 125 of 213 (58.7 %) of the open reading frames were
found to be recognized by either CD4+ only or by both CD4+
and or CD8+ T cells [30]. In healthy CMV-seropositive indi-
viduals, the frequency of CMV-specific CD4+ memory T cells
has been reported to reach a median of 9.1 % [30]. This
frequency reached even 40 % in some donors suggesting that,
as for CD8+ CTL, high frequencies of CMV-specific CD4+ T
cells are mandatory to control CMV reactivation [31]. Ac-
cordingly, gB-specific cytotoxic CD4+ T cells have been
successfully isolated and expanded in vitro [24, 28].
In clinical trials involving a recombinant gB, it will be
essential to have reliable monitoring of the anti-gB CD4+
response. Several strategies to identify HLA-class II epitopes
can be considered. A first classical approach is based on the
location of candidate peptides carrying consensus anchor
motives for a certain HLA in the protein sequence by in silico
algorithms [32]. However, the selection of these candidate
peptides harboring anchor residues is limited by less accurate
predictive methods of HLA-class II binding peptides as com-
pared to HLA-class I binding peptides. Moreover, the accura-
cy of these predictions must be confirmed empirically [32], as
peptide binding to the HLA molecules does not always guar-
antee that the epitope is naturally processed. For example,
CD4+ T cells specific for MAGE-A3161-175 or for MAGE-
A3171-185 peptides were obtained upon in vitro stimulation of
PBMCs from melanoma patients. Recognition of the respec-
tive native epitopes was tested by recognition of autologous
EBV-B cells engineered to express MAGE-A3 either in the
cytoplasm or in the endosomal/lysosomal compartment and
the HLA-class II positive autologous melanoma. These CD4+
T cells failed to recognize the naturally processed epitope,
suggesting that the MAGE-A3161-175 and MAGE-A3171-185
peptides do not contain natural epitopes produced after pro-
cessing through both the endogenous and the exogenous path-
ways [33]. We produced gB-polypeptides using a simple, cost
saving bacterial expression system and used the exogenous
processing pathway of autologous EBV-B cells to identify the
naturally processed gB-peptide recognized by established
CD4+ T cell clones. This technique offers the advantage of
avoiding the synthesis of a peptide library, for which the size
and cost can be prohibitive, and is mainly applicable for the
determination of CD4+ T-cell epitopes derived from large
proteins or from proteins of unknown sequence derived from
a cDNA expression library [34]. Morevoer, the isolated CD4+
T-cell clones described here have additional interest, as their
T-cell receptors (TCRs) might be used both for diagnostic and
therapeutic purposes. Firstly, the soluble TCRs might help
identifying and tracing HLA-peptide complexes on the sur-
face of CMV-infected cells and tissues. Furthermore, gB-





















































































Fig. 5 Characteristics of clone B3A5. The procedure used for clone
B3A5 was the same as the one described in Figs. 2 and 3. a Recogni-
tion of EBV-B cells loaded with recombinant gB-expressing bacteria
by CD4+ T-cell clone B3A5. b Inhibition of the gB peptide recognition
by anti-HLA-DP, -DQ or -DR Abs. c Identification of the minimal gB
epitopes recognized by by CD4+ T-cell clone B3A5. d HLA-class II
restriction analysis of the gB epitope recognized by CD4+ T-cell clone
B3A5
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specific TCR-transgenic CD4+ T cells could have clinical
application. The development of a CMV-specific T-cell ther-
apy in hematopoietic stem cell (HSC) transplant is indeed
highly warranted, because patients transplanted with alloge-
neic HSC from CMV-seronegative donors are at high risk of
developing CMV-related disease. Transgenic pp65-specific
CD8+ T cells were already successfully generated from pri-
mary T cells of CMV-seronegative donors by retroviral TCR
transfer [35]. In concert with pp65 specific-TCR transgenic
CD8+ T cells, gB-specific TCR-transgenic T cells could rep-
resent promising tools for adoptive T cell therapy in HSC
transplant patients.
To our knowledge, the characterization of established gB-
specific CD4+ clones has led to the identification of a single
gB-derived epitope, namely DYSNTHSTRYV (DYS), which
is restricted by HLA DRB*0701 [24]. In the present study, we
have isolated several human CD4 clones that recognize epito-
pes from CMV-gB restricted by HLA-DR7, HLA-DP1 and
HLA-DP2 molecules. The gB190-204 epitope identified in this
study contains the DYS epitope that has already been reported
to be presented by HLA-DR7 [24]. Surprisingly, the gB601-613
peptide, which contains the four known anchor residues com-
mon for HLA-DP2 and HLA-DP4 [26], was only presented by
HLA-DP2 to the relevant CD4 clone. Given the high allele
frequencies of HLA-DPB1*0401 andDPB1*0402 worldwide,
the binding of this epitope and its recognition by anti-gB CD4+
T cells in HLA-DP4 subjects deserves further investigation, as
this would open the possibility of using this peptide for the
purposes of clinical monitoring of a large proportion of sub-
jects vaccinated with gB. Obviously, further identification of
gB-derived epitopes to cover additional HLA allotypes is
highly desirable.
Remarkably, two of the anti-gB CD4+ T-cell clones estab-
lished in this work recognized autologous EBV-B cells
infected with the Towne laboratory strain, suggesting that
the gB epitopes have access to the endogenous HLA-class II
presentation pathway of the CMV-infected cells and that the
recognition process of HLA-class II infected cells could occur
in vivo. The exact mechanism governing the presentation of
endogenous gB products on HLA-class II molecules still
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Fig. 6 Recognition of HCMV-
infected cells by two CD4+
T-cell clones directed against
gB and expression of GrB by
clone B3A5. gB-specific CD4+
T-cell clones B3A5 (a) or 1A10
(b) recognize autologous EBV-
B cells infected with the Towne
laboratory strain. CD4+ T-cell
clones were stimulated with
autologous EBV-B cells, loaded
or not either with a recombinant
gB protein or with the relevant
gB-derived peptide, or infected
with the Towne CMV strain
(10 pfu/cell). IFN-γ production
in the supernatant was mea-
sured by ELISA after 36 h. (c)
Anti-GrB labeling of clone
B3A5. Percentages of
CD3+CD4+ or CD4+GrB+
double positive cells are indi-
cated in the upper right corner
of each subpanel
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remains to be elucidated. Our data are in accordance with
recent data showing that gB can be presented directly from
CMV-infected HLA-class II cells to gB-specific CD4+ cyto-
toxic Tcells, able to kill target cells without the need for cross-
presentation [24, 28]. Our results illustrate the possibility to
follow the amplification of such clones of cytotoxic CD4+ T
cells, which should be considered as important in the design of
vaccine strategies.
Conclusion
The generation of appropriate CD4+ T-cell responses that are
likely to help increase baseline gB-specific antibody levels
should be considered and would require additional evaluation
in future clinical trials. To that end, we have applied a simple
and broadly applicable method to characterize several novel,
naturally processed CD4+ T-cell epitopes from the CMV gB
protein that will help investigating the role of natural and
vaccine-induced CD4+ T-cell responses against CMV. Finally,
our data may contribute to analysis of the threshold of the anti-
gB CD4+ T-cell immune response required in protection
against congenital CMV infection.
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